RXRXHealthcare · BiotechnologyThe 7 Wall Street analysts covering Recursion Pharmaceuticals, Inc. hold a median 12-month price target of $7 — +117.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 8 Sept 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Recursion Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on RXRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +117.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $5.00 → $5.50 |
| 7 May 2026 | Needham | Reiterates | Buy | $8.00 |
| 30 Apr 2026 | JP Morgan | Maintains | Overweight | — |
| 26 Feb 2026 | B of A Securities | Maintains | Neutral | — |
| 26 Feb 2026 | Needham | Reiterates | Buy | — |
| 17 Dec 2025 | JP Morgan | Upgrade | Overweight | — |
| 11 Sept 2025 | Needham | Reiterates | Buy | — |
| 8 July 2025 | Needham | Reiterates | Buy | — |
| 3 July 2025 | Morgan Stanley | Assumes | Equal-Weight | $5.00 |
| 16 June 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 May 2025 | Needham | Maintains | Buy | — |
| 10 Apr 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 8 Apr 2025 | Needham | Reiterates | Buy | — |
| 28 Feb 2025 | Leerink Partners | Maintains | Market Perform | — |
| 6 Feb 2025 | Needham | Reiterates | Buy | — |
| 8 Jan 2025 | Keybanc | Maintains | Overweight | — |
| 11 Dec 2024 | Needham | Reiterates | Buy | — |
| 20 Nov 2024 | Needham | Reiterates | Buy | — |
| 7 Nov 2024 | Needham | Reiterates | Buy | — |
| 4 Sept 2024 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RXRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Sept 2026, Recursion Pharmaceuticals, Inc. returned −31.6% against +18.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 7% of US stocks
Cheaper than 44% of US stocks
Cheaper than 75% of US stocks
Higher than 4% of US stocks
Higher than 8% of US stocks
Higher than 2% of US stocks
Higher than 4% of US stocks
Higher than 58% of US stocks
Higher than 20% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Recursion Pharmaceuticals, Inc. has a market value of $1.7B and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $53.9M. The latest quarter shrank 60.1% year on year.
Net income over the same four quarters: −$518.9M, a −962.0% net margin.
Diluted earnings per share, trailing twelve months: $−1.04.
Free cash flow in the twelve months to 30 June 2026: −$354.3M.
Trailing P/E: −2.2×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Recursion Pharmaceuticals, Inc. employs 600 people — $90K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Recursion Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The Motley Fool listed Recursion Pharmaceuticals among beaten-down stocks to avoid, noting that while the company claims its drug-development approach is superior, it has yet to prove that claim so far.
Why it matters — An RXRX watcher would care because the article questions the company's ability to validate its proprietary drug-development platform with concrete results.
Recursion Pharmaceuticals reported earnings 30 days ago, and its stock has risen 8.2% since then. The article examines what may come next for the company's shares following the earnings report.
Why it matters — A stock watcher would care because this item tracks the company's share movement since its latest earnings report and looks at what could drive future performance.
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs noted as potential growth catalysts.
Why it matters — A RXRX watcher would care because pipeline expansion across oncology and rare diseases could signal potential long-term growth catalysts for the company.
A Zacks Investment Research item highlights Recursion Pharmaceuticals (RXRX) alongside SDGR, RLAY, and ABSI as companies using AI-powered platforms to transform drug discovery while advancing their proprietary clinical pipelines. The piece positions these firms among AI-driven drug discovery stocks to watch as AI reshapes pharma.
Why it matters — A RXRX watcher would care because the item reinforces Recursion's standing as a notable AI-powered drug discovery platform amid broader industry shifts toward AI in pharma.
Recursion Pharmaceuticals' CFO and President of Recursion U.K., Ben Taylor, discussed the company's use of artificial intelligence to generate and analyze biological data during a BofA Global Research virtual conference. He highlighted how the AI platform aims to improve drug discovery, advance internal therapeutic programs, and support collaborations with larger pharmaceutical companies, while also covering pipeline updates and progress with Roche.
Why it matters — RXRX watchers would care because the presentation details how Recursion's AI-driven approach supports its drug discovery efforts and its collaboration with Roche, offering insight into the company's strategy and pipeline direction.
The 7 Wall Street analysts covering Recursion Pharmaceuticals, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Recursion Pharmaceuticals, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Recursion Pharmaceuticals, Inc. 43 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Sept 2026, Recursion Pharmaceuticals, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +117.7% from the last close, and Ticker Nerd's factor model ranks Recursion Pharmaceuticals, Inc. 43 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Recursion Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RXRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
Recursion Pharmaceuticals, Inc. returned -31.6% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Recursion Pharmaceuticals, Inc. Class A Common Stock represents ownership in Recursion Pharmaceuticals, a clinical-stage TechBio company focused on industrializing drug discovery through data-driven biology and chemistry.
The most recent item we track (The Motley Fool, 8 Sept 2026): "2 Beaten-Down Stocks to Avoid Right Now". The Motley Fool listed Recursion Pharmaceuticals among beaten-down stocks to avoid, noting that while the company claims its drug-development approach is superior, it has yet to prove that claim so far.
Recursion Pharmaceuticals, Inc. Class A Common Stock represents ownership in Recursion Pharmaceuticals, a clinical-stage TechBio company focused on industrializing drug discovery through data-driven biology and chemistry. The company uses automation, artificial intelligence, machine learning, and engineering to map biological systems and identify novel therapeutic candidates. Its work centers on building a technology-enabled platform for discovering and advancing medicines across areas such as oncology, rare disease, and other complex conditions. Recursion also operates in a research and development environment that combines wet-lab biology with computational tools to improve the efficiency of early-stage drug discovery. Headquartered in Salt Lake City, Utah, Recursion Pharmaceuticals plays a specialized role in the biotechnology market as a developer of platform-based drug discovery capabilities and clinical-stage therapeutic programs.
CEO Dr. Najat Khan Ph.D. · 600 employees · United States · https://www.recursion.com
